Crinetics Pharmaceuticals
CRNX

$54.36

1.91%

Market Cap: 4.29B

About: Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Employees: 210

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 28 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

61% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 28

50% more capital invested

Capital invested by funds: $2.51B [Q4 2023] → $3.76B (+$1.25B) [Q1 2024]

44% more funds holding in top 10

Funds holding in top 10: 9 [Q4 2023] → 13 (+4) [Q1 2024]

42% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 55

21% more call options, than puts

Call options by funds: $34.1M | Put options by funds: $28.1M

9% more funds holding

Funds holding: 181 [Q4 2023] → 198 (+17) [Q1 2024]

2.59% less ownership

Funds ownership: 105.77% [Q4 2023] → 103.18% (-2.59%) [Q1 2024]

See Fund Rankings

Research analyst outlook

28 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$48

12%

downside

Avg. target

$64

18%

upside

High target

$97

78%

upside

28 analyst ratings

28 positive

100%

0 neutral

0%

0 negative

0%

JP Morgan Jessica Fye	1%downside $54	Overweight Maintained	9 Jul 2024
Piper Sandler Yasmeen Rahimi	78%upside $97	Overweight Maintained	2 Jul 2024
HC Wainwright & Co. Douglas Tsao	10%upside $60	Buy Reiterated	28 Jun 2024
JMP Securities Jonathan Wolleben	47%upside $80	Market Outperform Reiterated	4 Jun 2024
Oppenheimer Leland Gershell	36%upside $74	Outperform Maintained	4 Jun 2024

See Analyst Rankings

Financial journalist opinion

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET that day to discuss financial results and provide a business update.

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 137,900 shares of its common stock to eighteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 Biotech Stocks to Boost Your Portfolio to Peak Health

While innovations such as artificial intelligence have become all the rage, there's another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven't considered the sector, it's really time to focus on biotech stocks.

7 Biotech Stocks to Boost Your Portfolio to Peak Health

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner

Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2024, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its common stock to nine new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investors Business Daily

Crinetics Unveils 'Stunning' Results In Highly Anticipated Study

Crinetics unveiled "stunning" results from a study of a major drug. Crinetics stock rose Monday.

Crinetics Unveils 'Stunning' Results In Highly Anticipated Study

Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine

Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS)

100% of Participants (n=6) With CAH Maintained Androstenedione (A4) Below the Upper Limit of Normal at all Time Points on Atumelnant (80 mg)

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS)

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D.

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more than 30 years of experience spanning clinical practice and pharmaceutical industry medical affairs.

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D.

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

Positive data released from 4 patients from phase 2 study that took Atumelnant for congenital adrenal hyperplasia, showing reductions in key biomarkers of A4 and 17-OHP. An NDA submission of Paltusotine for the treatment of patients with Acromegaly expected in the 2nd half of 2024. Additional results from phase 2 open-label study, using Atumelnant for patients with CAH, to be presented at ENDO Conference on June 3rd 2024 at 12:00 to 1:30 p.m. ET.

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

See News Rankings